Sun Pharma
Market cap ₹4.19 L Cr
- P/E
- 34.68
- Day range
- ₹1,735.20 – ₹1,765.40
- 52-week range
- ₹1,583.70 – ₹2,046.90
- Volume
- 10.64 L
- Open
- ₹1,757.40
- Prev close
- ₹1,758.00
Latest results · Q1 FY27(consolidated)Revenue ₹15,300 Cr+10.5%Profit ₹2,901 Cr+26.5%Margin 19.0%YoY vs the same quarter last year
No red flags in exchange filings: no rising pledge, promoter selling, surveillance or critical filing on record.
SUNPHARMA in NSE indices and F&O
F&O margin for one lot of SUNPHARMA (350 shares)Research profile
Composite 67 / 100Factor percentiles
Derived metrics
- Earn. yield
- 2.9%
- Graham no.
- ₹642.07
- vs Graham
- -63.3%
- ROE ÷ P/B
- 2.9%
- 12-1 mom.
- +11.6%
- Return / vol
- 0.30
- Magic Formula
- #254
- Piotroski
- 2/6
- FCF yield
- 2.1%
- PEG
- 1.34
Appears in 14 scans
Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.
Peer comparison
All 67 in Pharma| Company | M-cap | P/E | P/B | ROE | ROCE | OPM | D/E | Sales YoY |
|---|---|---|---|---|---|---|---|---|
| Sun PharmaSUNPHARMA | ₹4.19 L Cr | 34.68 | 5.02 | 14.8% | 21.0% | 29.0% | 0.06 | +10.5% |
| Divi's LaboratoriesDIVISLAB | ₹2.38 L Cr | 81.21 | 14.52 | 16.2% | 22.0% | 41.0% | 0.00 | +27.8% |
| Torrent PharmaTORNTPHARM | ₹1.72 L Cr | 76.43 | 9.37 | 26.8% | 15.0% | 33.0% | 0.77 | +50.8% |
| Zydus LifesciencesZYDUSLIFE | ₹1.13 L Cr | 25.17 | 4.20 | 20.1% | 21.0% | 24.0% | 0.46 | +22.0% |
| Apollo HospitalsAPOLLOHOSP | ₹1.11 L Cr | 53.19 | 11.54 | 22.6% | 17.0% | 16.0% | 0.90 | +20.6% |
| CiplaCIPLA | ₹1.08 L Cr | 32.09 | 3.12 | 11.8% | 15.0% | 17.0% | 0.02 | +2.3% |
| Laurus LabsLAURUSLABS | ₹1.06 L Cr | 97.38 | 20.06 | 18.2% | 18.0% | 32.0% | 0.48 | +29.0% |
| Dr. Reddy's LabsDRREDDY | ₹1.02 L Cr | 36.60 | 2.73 | 11.6% | 13.0% | 11.0% | 0.20 | -5.5% |
| Sector median | ₹23,579 Cr | 41.61 | 5.60 | 15.1% | 17.0% | 25.0% | 0.16 | +20.7% |
Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.
Latest news
Updated 4d agoHeadlines about Sun Pharma from the last two weeks in the financial press. Stories belong to their publishers; Parasram India does not endorse them.
Key metrics
- P/E (TTM)
- 33.2
- EPS (TTM)
- ₹50.44
- Price / Book
- 5.02
- ROE (FY26)
- 14.8%
- ROCE (latest year)
- 21%
- Dividend yield
- 0.92%
Moving averages (NSE)
- 20-day
- ₹1,785.07
- Price below
- 50-day
- ₹1,850.33
- Price below
- 200-day
- ₹1,808.63
- Price below
Charts & trends
From company filings. Amounts in ₹ crore.
Revenue, profit & margin - quarterly
₹ crore; a loss shows red. Operating margin below, same periods.
- Revenue
- Net profit
Operating margin
Who owns the company
% of equity by quarter, latest Sept 2026
- Promoter
- DII
- FII
- Public
- Government
Cash flows
Where cash came from and went, by fiscal year (₹ crore)
- Operating
- Investing
- Financing
- Free cash flow
Return on equity
Net profit over shareholders' equity, by fiscal year
Equity vs debt
Shareholders' equity against borrowings (₹ crore); the ratio below, same years.
- Equity
- Debt
Debt to equity
Dividends per share
₹ by fiscal year of the ex-date; the latest year runs to date.
Financial statements
| Line item | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 12,192 | 12,381 | 11,983 | 12,653 | 13,291 | 13,675 | 12,959 | 13,851 | 14,478 | 15,521 | 14,612 | 15,300 |
| Expenses | 9,013 | 8,904 | 8,948 | 9,045 | 9,352 | 9,666 | 9,243 | 9,550 | 9,951 | 10,572 | 10,658 | 10,882 |
| Operating Profit | 3,179 | 3,477 | 3,035 | 3,608 | 3,939 | 4,009 | 3,716 | 4,302 | 4,527 | 4,948 | 3,954 | 4,418 |
| OPM % | 26% | 28% | 25% | 29% | 30% | 29% | 29% | 31% | 31% | 32% | 27% | 29% |
| Other Income | 294 | 180 | 504 | 533 | 354 | 149 | 251 | -354 | 470 | 89 | 458 | 520 |
| Interest | 49 | 35 | 74 | 62 | 69 | 52 | 49 | 75 | 100 | 78 | 86 | 100 |
| Depreciation | 633 | 622 | 650 | 655 | 626 | 631 | 664 | 701 | 730 | 732 | 775 | 739 |
| Profit before tax | 2,791 | 3,000 | 2,816 | 3,424 | 3,598 | 3,476 | 3,254 | 3,173 | 4,168 | 4,227 | 3,551 | 4,099 |
| Tax % | 14% | 14% | 5% | 16% | 16% | 16% | 34% | 27% | 25% | 20% | 23% | 29% |
| Net Profit | 2,385 | 2,561 | 2,659 | 2,861 | 3,037 | 2,913 | 2,154 | 2,293 | 3,125 | 3,381 | 2,710 | 2,901 |
| EPS in Rs | ₹9.90 | ₹10.52 | ₹11.06 | ₹11.82 | ₹12.67 | ₹12.10 | ₹8.96 | ₹9.50 | ₹13.00 | ₹14.04 | ₹11.31 | ₹12.06 |
From company filings, updated 25 Oct 2026. Consolidated figures where the company reports them. Information only, not investment advice.
Working-capital cycle
-2 days since Mar 2021
-15 days since Mar 2021
+65 days since Mar 2021
-82 days since Mar 2021
+3 days since Mar 2021
Strengths, risks & growth
Sun Pharmaceutical Industries Ltd is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharma Ingredients (APIs). The company and its subsidiaries has various manufacturing facilities spread across the world with trading and other incidental and related activities extending to global market. [1] It is the largest pharmaceutical company in India. [2]
Strengths
- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 34.1%
Risks
- Promoter holding has decreased over last quarter: -1.80%
- The company has delivered a poor sales growth of 11.8% over past five years.
Compounded Sales Growth
- 10 Years
- +7%
- 5 Years
- +12%
- 3 Years
- +10%
- TTM
- +11%
Compounded Profit Growth
- 10 Years
- +10%
- 5 Years
- +17%
- 3 Years
- +13%
- TTM
- +10%
Stock Price CAGR
- 10 Years
- +9%
- 5 Years
- +17%
- 3 Years
- +16%
- 1 Year
- +3%
Return on Equity
- 10 Years
- +14%
- 5 Years
- +16%
- 3 Years
- +16%
- Last Year
- +16%
Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.
Shareholding pattern
| Holder | Dec 2025 | Mar 2026 | Jun 2026 | Sept 2026 | Change |
|---|---|---|---|---|---|
| Promoter | 54.48% | 54.48% | 54.48% | 52.68% | -1.80 pp |
| FII | 16.12% | 15.94% | 14.54% | 14.36% | -0.18 pp |
| DII | 20.72% | 21.00% | 22.06% | 22.27% | +0.21 pp |
| Government | 0.11% | 0.11% | 0.11% | 0.00% | -0.11 pp |
| Public | 8.57% | 8.48% | 8.81% | 10.70% | +1.89 pp |
Filed with NSE for Sept 2026: promoters 52.68%, public 47.32% · XBRL filing
Analysts & fund holdings
Who holds the shares, quarter by quarter
Mutual funds 13.01% (+0.17 pp)- Promoters52.7%
- Foreign institutions14.4%
- Mutual funds13.0%
- Insurance6.8%
- Other domestic institutions2.5%
- Retail4.4%
- Others6.3%
| Fund | % of company | % of fund | 3-month change |
|---|---|---|---|
| ICICI Pru Value Fund | 0.59% | 4.37% | -0.42 pp |
| ICICI Pru Aggressive Hybrid Fund | 0.44% | 3.53% | -0.07 pp |
| HDFC Balanced Advantage Fund | 0.38% | 1.55% | +0.09 pp |
| ICICI Pru Large Cap Fund | 0.38% | 2.08% | -0.44 pp |
| SBI Aggressive Hybrid Fund | 0.34% | 1.67% | +1.67 pp |
Scorecard
- Performance
- Avg
- Valuation
- High
- Growth
- Low
- Profitability
- High
- Entry point
- Good
- Red flags
- Low
Analyst coverage, holdings and scorecard from market data; not a recommendation by Parasram India.
Risk & trend
From 275 daily sessions to 23 Oct 2026.
Risk
- Volatility (1Y)
- 19.2%
- Downside volatility
- 19.0%
- Worst 5% of days
- 2.0%
- Average of that tail
- 2.8%
- Max drawdown (1Y)
- 13.2%
- Below its peak
- 12.6%
Against the market
- Beta vs Nifty 50
- 0.49
- Correlation
- 0.34
- Relative strength (3M)
- -5.2%
- ATR (14)
- 1.9%
Return
- Return 1M
- -5.3%
- Return 3M
- -10.5%
- Return 6M
- +4.7%
- Return 1Y
- +5.7%
- vs 200-day average
- -3.4%
Momentum
- RSI (14)
- 37.2
- MACD histogram
- 0.70
- Stochastic %K
- 34.0
- ADX (14)
- 41.5
- +DI / −DI
- 7.0 / 20.1
- Money flow index
- 34.6
Participation
- Delivery (20d avg)
- 62.7%
- vs its 60-day baseline
- -1.5 pts
- Volume vs 20-day
- -0.8σ
- Close vs day's VWAP
- +0.1%
- 52-week position
- 39 / 100
These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.
Financial quality
From consolidated statements to 31 Mar 2026.
Piotroski F-Score
2 of 6 tested
- Return on assets positive — passed
- Operating cash flow positive — not testableno cash flow statement for this period
- Return on assets improving — passed
- Cash flow exceeds profit — not testableneeds cash flow and profit against assets
- Debt to assets falling — failed
- Current ratio improving — failed
- No new equity issued — not testableno share count is collected, and financing cash flow mixes equity with debt
- Operating margin improving — failed
- Asset turnover improving — failed
- Free cash flow
- ₹8,810 Cr
- FCF yield
- 2.1%
- Cash conversion
- 1.08
- Accruals ratio
- -0.008
- Net debt
- -₹5,143 Cr
- Net debt / equity
- -0.06
- EV / sales
- 6.91
- PEG
- 1.34
- Capex intensity
- 6.2%
- Revenue CAGR
- 12.8%
- Profit CAGR
- 25.8%
Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.
Model simulation
30 independent runs of NeoQuasar/Kronos-small, conditioned on daily bars to 23 Oct 2026, simulating 10 sessions ahead.
Lower edge (10th percentile)
₹1,693.53
-3.1%
Upper edge (90th percentile)
₹1,758.83
+0.6%
The marker is the last close, ₹1,748. Eight of every ten simulated runs ended inside this range; the middle run ended at ₹1,720.21 (-1.6%), which is the centre of the simulation and not an expected or target price.
The model reads price history only. It has not seen this company's results, its filings, its industry or anything that happened after 23 Oct 2026. Ranges widen with horizon because the further out the simulation runs, the less the recent past constrains it.
Corporate actions
- dividend₹5.00
Dividend - Rs 5 Per Share
7 Jul 2026ex-date - dividend₹11.00
Interim Dividend - Rs 11 Per Share
5 Feb 2026ex-date - dividend₹5.50
Dividend - Rs 5.50 Per Share
7 Jul 2025ex-date - dividend₹10.50
Interim Dividend - Rs 10.50 Per Share
6 Feb 2025ex-date - dividend₹5.00
Dividend - Rs 5 Per Share
12 Jul 2024ex-date - dividend₹8.50
Interim Dividend - Rs 8.50 Per Share
9 Feb 2024ex-date - dividend₹4.00
Dividend - Rs 4 Per Share
28 Jul 2023ex-date - dividend₹7.50
Interim Dividend - Rs 7.50 Per Share
8 Feb 2023ex-date - dividend₹3.00
Dividend - Rs 3 Per Share
19 Aug 2022ex-date - dividend₹7.00
Interim Dividend - Rs 7 Per Share
9 Feb 2022ex-date - dividend₹2.00
Annual General Meeting/Dividend - Rs 2 Per Share
23 Aug 2021ex-date - dividend₹5.50
Interim Dividend - Rs 5.50 Per Share
9 Feb 2021ex-date - dividendNot available — not reported in this filing
Annual General Meeting/Dividend - Re 1 Per Share
19 Aug 2020ex-date - dividend₹3.00
Interim Dividend - Rs 3 Per Share
17 Feb 2020ex-date - dividend₹2.75
Annual General Meeting/Dividend - Rs 2.75 Per Share
20 Aug 2019ex-date - dividend₹2.00
Annual General Meeting/Dividend Rs 2 Per Share
17 Sept 2018ex-date - dividend₹3.50
Annual General Meeting/Dividend - Rs 3.50 Per Share
18 Sept 2017ex-date - dividendNot available — not reported in this filing
Annual General Meeting/Dividend Re 1/- Per Share
8 Sept 2016ex-date - buybackNot available — not reported in this filing
Buy Back
14 Jul 2016ex-date - dividend₹3.00
Annual General Meeting/ Dividend - Rs 3/- Per Share
21 Oct 2015ex-date
Company announcements
Press Release
Earnings call for the financial results of the second quarter on 30 October 2026
Sun Pharmaceutical Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/10/2026 ,inter alia, to consider and approve the Unaudited ....
Submission of Confirmation Certificate
Update on Credit Ratings
Outcome of the Board Meeting held on 12 October 2026
Outcome of the Board Meeting held on 12 October 2026
Sun Pharmaceutical Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/10/2026 ,inter alia, to consider and approve the issuance ....
Press Release
Newspaper publication about Postal Ballot/E-voting October 2026
Notice of Postal ballot October 2026
Press Release is enclosed
Newspaper publication about the opening of Special Window for transfer of physical shares
ESG Overview for FY 2025-26
Completion and Result of Postal Ballot dated 25 August 2026
Filed with BSE (scrip 524715); the last 45 days. Documents open at bseindia.com.
Documents
Annual reports
Earnings calls
- Sep 2026Slides
- Aug 2026TranscriptSlidesRecording
- May 2026Transcript
- May 2026TranscriptSlidesRecording
- Feb 2026TranscriptSlidesRecording
- Dec 2025Slides
Credit ratings
- Rating update · 13 Oct from icra
- Rating update · 13 Oct from crisil
- Rating update · 4 Aug from crisil
- Rating update · 6 May from crisil
- Rating update · 5 May from icra
- Rating update · 17 Mar from crisil
Documents open at BSE or the rating agency that issued them.
Sourced from the company's NSE XBRL filing dated 31 Jul 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.
Sun Pharma: common questions
Answered from the figures on this page.
